| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.008 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.008 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.09 | 0.008 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.008 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.008 |
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | 0.099 | 0.008 |
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.01 |
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | 0.095 | 0.01 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.01 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | 0.097 | 0.01 |